Cargando…
Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
The Centers for Disease Control and Prevention (CDC) categorized carbapenem-resistant Enterobacterales (CRE) infections as an “urgent” health care threat requiring public attention and research. Certain patients with CRE infections may be at higher risk for poor clinical outcomes than others. Eviden...
Autores principales: | Rebold, Nicholas, Lagnf, Abdalhamid M., Alosaimy, Sara, Holger, Dana J., Witucki, Paige, Mannino, Andrew, Dierker, Michelle, Lucas, Kristen, Kunz Coyne, Ashlan J., El Ghali, Amer, Caniff, Kaylee E., Veve, Michael P., Rybak, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927167/ https://www.ncbi.nlm.nih.gov/pubmed/36622246 http://dx.doi.org/10.1128/spectrum.02647-22 |
Ejemplares similares
-
High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023) -
Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
por: Holger, Dana J., et al.
Publicado: (2022) -
2779. Early Administration of Ceftazidime-Avibactam for Carbapenem-Resistant Enterobacterales Is Associated with Improved Clinical Success
por: Coyne, Ashlan J Kunz, et al.
Publicado: (2023) -
1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
por: Ghali, Amer El, et al.
Publicado: (2022) -
1033. Unexpected Allies: Vancomycin and Cefazolin Combination Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Caniff, Kaylee E, et al.
Publicado: (2023)